Annual Decline in Pentraxin 3 Is a Risk of Vascular Access Troubles in Hemodialysis Patients
Table 1
Characteristics of the subjects with stratification by absence or presence of vascular access troubles.
Total ( = 76)
Absence ( = 56)
Presence ( = 20)
Median
IQC
Median
IQC
Median
IQC
Gender (% man)
60
—
64
—
45
—
Diabetes (%)
41
—
38
—
50
—
Age (years)
67
58–77
66
58–77
67
58–77
Dialysis-period (years)
5.4
2.3–9.4
5.8
2.8–9.6
4
2.0–7.4
Body mass index (kg/m2)
21.9
19.6–24.0
21.2
19.4–24.0
22.5
20.5–24.0
RAS-inhibitor usage (%)
80
—
82
—
72
—
Statin usage (%)
14
—
11
—
22
—
Total protein (g/dL)
6.6
6.3–6.9
6.5
6.3–6.8
6.6
6.2–7.0
Albumin (g/dL)
3.3
3.0–3.4
3.3
3.0–3.5
3.3
3.0–3.4
Calcium (mg/dL)
8.9
8.5–9.8
8.8
8.4–9.8
9
8.6–9.9
Inorganic phosphorus (mg/dL)
5.2
4.6–6.1
5.2
4.6–5.8
5.3
4.6–6.3
Total cholesterol (mg/dL)
165
139–182
167
139–182
158
138–181
LDL-C (mg/dL)
95
77–112
95
73–113
93
77–107
Triglyceride (mg/dL)
93
72–145
93
74–136
97
72–174
Intact parathyroid hormone (pg/mL)
109
70–157
114
75–159
79
48–130
Hemoglobin (g/dL)
11
10.2–11.5
11
10.2–11.5
10.9
10.0–11.9
Ferritin (ng/mL)
65.6
40.8–114.9
66.2
41.1–116.2
62.9
40.6–114.9
Serum iron (mg/dL)
63.5
48.5–84.8
64
48.5–87.8
62
47.3–74.8
2-microglobulin (mg/L)
29.1
25.5–32.2
28.9
24.7–31.9
29.9
26.8–34.3
PTX3 (ng/mL)
4.2
3.1–5.4
4.1
3.1–5.4
4.2
3.1–5.8
hsCRP (mg/dL)
0.66
0.56–0.73
0.64
0.54–0.72
0.68
0.62–0.75
Data at baseline year was presented as median and interquartile range (IQC). RAS: renin-angiotensin system, LDL-C: low-density lipoprotein cholesterol, PTX3: pentraxin 3, and hsCRP: high-sensitivity C-reactive protein.
